# **ADVANCING CANCER RESEARCH THROUGH** COLLABORATION

Bristol Myers Squibb has long believed that the **future of cancer** research breakthroughs is dependent on investments in science and partnerships.

Our collaborations with academia, advocacy groups, government, and biotech companies accelerate our collective ability to address essential scientific questions in oncology and hematology research, helping to facilitate innovation and drug discovery.




The **II-ON** (International Immuno-Oncology Network) is a global peer-to-peer collaboration between Bristol Myers Squibb and academia that aims to advance cancer research and translational medicine to improve patient outcomes.

Launched in 2012, the II-ON was one of the first networks to bring academia and industry together to further oncology research.

The II-ON has generated cutting-edge data that have informed the development of new agents, yielded publications and produced some of the earliest findings on a variety of biomarkers and target identification and validation.


#### THE II-ON PARTNERS COLLABORATE TO:



#### **BY THE NUMBERS:**

350+ 75+ publications investigators 250+ research projects member tumor types organizations

### THE II-ON'S RESEARCH FOCUSES ON 3 SCIENTIFIC PILLARS:



Identifying patient populations likely to benefit from therapies

**Exploring** novel combination therapies

W PO Oc In DO A

FOUNDATIONAL FOCUS OF UNDERSTANDING CANCER BIOLOGY

## MEMBER ORGANIZATIONS





- Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center
- Clinica Universidad Navarra
- Columbia University Medical Center Dana-Farber Cancer Institute
- The Earle A. Chiles Research Institute
- (Providence Health & Services) **Institut Gustave Roussy**
- Istituto Nazionale per lo Studio e la Cura dei
- Tumori "Fondazione G. Pascale"

- Memorial Sloan-Kettering Cancer Center
- National Cancer Center Japan The Netherlands Cancer Institute
- Peter MacCallum Cancer Center
- The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
- The University of Chicago • University College London
- West German Cancer Center/University Hospital Essen
- Yale Cancer Center



about Bristol Myers Squibb's TO LEARN MORE research partnerships, please visit us at www.bms.com

